Bispecific therapy – treatment setting and management of short-term adverse events

EP: 1.Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP: 2.Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP: 3.Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP: 4.Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP: 5.Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP: 6.Panel Discuses Use of CD19 Bispecifics in Sequencing

EP: 7.Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP: 8.Current Approach to Bridging Therapy in R/R DLBCL

EP: 9.Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP: 10.Management of CRS and ICANS with CAR T-cell Therapy

EP: 11.Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP: 12.Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

Now Viewing

EP: 13.Bispecific therapy – treatment setting and management of short-term adverse events

EP: 14.Bispecific therapy – management of long-term adverse events in the community setting

EP: 15.Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP: 16.Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

In patients treated with bispecific antibodies, what safety data are concerning to you?

What treatment guidelines do you have in place for CRS and ICANS and are they different for bispecifics vs CAR T cell?

Please comment on the use of dexamethasone as premedication to mitigate the occurrence of CRS. (Falchi L et al. 2023 ASH Annual Meeting. Abstract 3130.)

What is the clinical significance of prophylactic tocilizumab in managing CRS for bispecifics such as teclistamab? (van de Donk N et al. 2023 ASCO Annual Meeting. Abstract 8033.)